What is the link between immune checkpoint inhibitors and rheumatic diseases?

What are the most common immune-related adverse events in patients taking checkpoint inhibitors?

How should rheumatic side effects of checkpoint inhibitors be managed in everyday practice?

What does the rheumatologist need to know about checkpoint inhibitors?

How many drug innovations have there been for lupus over the past 20 years?

Why do you think so few therapies have succeeded in this disease?

What is driving the development of new therapies for lupus?

What changes can patients expect to see in the coming years?

How have treatment options changed for patients with RA over the last 20 years?

Are modern patients different to those we might have seen 20 years ago?

Are there data to support drug-free remission in RA?

Do you expect to see curative treatments for RA in the near future?

Biologics in SpA: Why are real-world data important?

Are SpA patients well represented in registries? Are there any difficulties with collecting data in this patient group?

What do new and emerging data tell us about biologics in SpA?

What’s new in the field of imaging in SpA?

What is the pathogenic role of ACPA in rheumatoid arthritis?

ACPA-positivity is defined as a poor prognostic factor in the EULAR guidelines – what are the best treatment options for these patients?

Does ACPA status define a patient’s disease progression?

What is the link between ACPA and periodontitis in patients with established RA?

The ACR recommendations for RA were last updated in 2015 – what are the significant changes that have come about in the meantime?

What are the key management updates that we will see in the 2020 revision?

When will the final paper be published?

What is pre-RA, and how can it be identified?

Do patients with pre-RA require treatment?

In what way can patients at risk of developing RA modify their risk factors?

Does identifying RA early in the disease course make it easier to treat?

How quickly was the rheumatology community able to start collecting data on COVID-19, and why is this important?

What are the key risk factors for increased susceptibility or worse infection course?

What advice would you give to help protect people with rheumatic diseases?

How did rheumatologists manage their patients during the COVID-19 pandemic?

What were the main challenges of remote consultations for rheumatology patients?